Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients

被引:5
|
作者
Bachmann, Friederike [1 ,2 ,3 ]
Budde, Klemens [1 ,2 ,3 ]
Suttorp, Norbert [2 ,3 ,4 ]
Lingscheid, Tilman [2 ,3 ,4 ]
Stegemann, Miriam Songa [2 ,3 ,4 ]
Osmanodja, Bilgin [1 ,2 ,3 ]
Schrezenmeier, Eva [1 ,2 ,3 ,5 ]
Duettmann, Wiebke [1 ,2 ,3 ]
Weber, Ulrike [1 ,2 ,3 ]
Naik, Marcel [1 ,2 ,3 ]
Lehner, Lukas Johannes [1 ,2 ,3 ]
Kahl, Andreas [1 ,2 ,3 ]
Duerr, Michael [1 ,2 ,3 ]
Eckardt, Kai-Uwe [1 ,2 ,3 ]
Waiser, Johannes [1 ,2 ,3 ]
Choi, Mira [1 ,2 ,3 ]
Halleck, Fabian [1 ,2 ,3 ]
机构
[1] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany
[5] Charite Univ Med Berlin, Berlin Inst Hlth, Clinician Scientist Program, BIH Acad, Berlin, Germany
关键词
SARS-CoV-2; kidney transplantation; immunosuppression; bamlanivimab; monoclonal antibodies; MORTALITY; DISEASE;
D O I
10.3389/ti.2022.10109
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Antiviral drugs have shown little impact in patient infected with acute respiratory coronavirus 2 (SARS-CoV-2). Especially for immunocompromised persons positive for SARS-CoV-2, novel treatments are warranted. Recently, the U.S. FDA has granted an emergency use authorization (EUA) to two monoclonal antibodies (mAb) targeting the viral spike protein: bamlanivimab and casivirimab and imdevimab. As per the EUA, all SARS-CoV-2 positive organ transplant recipients can receive mAb treatment.Patients and methods: We queried our center's transplant registry to identify SARS-CoV-2 infected recipients treated with single doses of either Bamlanivimab or casivirimab/imdevimab up to May 31, 2021. We analyzed clinical outcomes, renal function and virus-specific antibodies. The co-primary endpoints were hospitalization due to COVID-19 and SARS-CoV-2 RT-PCR negativity.Results: Thirteen patients at a median interval of 55 (IQR, 26-110) months from transplant were treated: 8 with bamlanivimab and 5 with casivirimab/imdevimab. In all, 4/13 (31%) patients were hospitalized at some time, while 11/13 (85%) achieved PCR negativity. 2/4 hospitalized patients received mAb as rescue treatment. Overall mortality was 23%, with one death attributable to transplant-associated lymphoma. All six patients infected with the B 1.1.7 variant were alive at last contact. Conclusion: mAb treatment appears effective when administered early to SARS-CoV-2-infected transplant recipients.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] INITIAL EXPERIENCE WITH SARS-COV-2-NEUTRALIZING MONOCLONAL ANTIBODIES IN KIDNEY OR COMBINED KIDNEY-PANCREAS TRANSPLANT RECIPIENTS
    Bachmann, F.
    Budde, K.
    Lingscheid, T.
    Osmanodja, B.
    Schrezenmeier, E. V.
    Duettmann, W.
    Weber, U.
    Naik, M.
    Lehner, L. J.
    Kahl, A.
    Duerr, M.
    Eckardt, K. -U.
    Waiser, J.
    Choi, M.
    Halleck, F.
    [J]. TRANSPLANT INTERNATIONAL, 2021, 34 : 34 - 35
  • [2] SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients
    Wang, Aileen X.
    Busque, Stephan
    Kuo, Jamie
    Singh, Upinder
    Roeltgen, Katharina
    Pinsky, Benjamin A.
    Chertow, Glenn M.
    Scandling, John D.
    Lenihan, Colin R.
    [J]. KIDNEY360, 2022, 3 (01): : 133 - 143
  • [3] In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients
    Benotmane, Ilies
    Jungbauer-Groznica, Martin
    Staropoli, Isabelle
    Planas, Delphine
    Dehan, Oceane
    Brisebarre, Angela
    Simon-Loriere, Etienne
    Fafi-Kremer, Samira
    Schwartz, Olivier
    Bruel, Timothee
    Caillard, Sophie
    [J]. TRANSPLANT INTERNATIONAL, 2024, 37
  • [4] Infections in recipients of a kidney-pancreas transplant
    Cervera, Carlos
    Moreno, Asuncion
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2007, 25 (05): : 345 - 355
  • [5] Underuse of SARS-CoV-2-Neutralizing Monoclonal Antibodies in Skilled Nursing Facilities
    Paules, Catharine I.
    Osevala, Nicole
    Lehman, Erik
    Heilbrunn, Emily S.
    Francis, Erica
    Hogentogler, R. Ellen
    Kong, Lan
    Kraschnewski, Jennifer L.
    [J]. JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2024, 25 (02) : 290 - 295
  • [6] Persistence of SARS-CoV-2 antibodies in kidney transplant recipients
    Benotmane, Ilies
    Gautier Vargas, Gabriela
    Velay, Aurelie
    Wendling, Marie-Jose
    Perrin, Peggy
    Fafi-Kremer, Samira
    Caillard, Sophie
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (06) : 2307 - 2310
  • [7] Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients
    Prendecki, Maria
    Clarke, Candice
    Gleeson, Sarah
    Greathead, Louise
    Santos, Eva
    McLean, Adam
    Randell, Paul
    Moore, Luke S. P.
    Mughal, Nabeela
    Guckian, Mary
    Kelleher, Peter
    Mcadoo, Stephen P.
    Willicombe, Michelle
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (12): : 2753 - 2756
  • [8] Conversion to sirolimus in a population of kidney and kidney-pancreas transplant recipients
    Almeida, M
    Martins, LS
    Dias, L
    Figueiredo, MJ
    Henriques, AC
    Sarmento, AM
    Cabrita, A
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (06) : 2777 - 2780
  • [9] The impact of hypoalbuminemia in kidney-pancreas transplant recipients
    Becker, BN
    Becker, YT
    Heisey, DM
    Leverson, GE
    Colllins, BH
    Odorico, JS
    D'Alessandro, AM
    Knechtle, SJ
    Pirsch, JD
    Sollinger, HW
    [J]. TRANSPLANTATION, 1999, 68 (01) : 72 - 75
  • [10] Late complications in kidney-pancreas transplant recipients
    Bruce, DS
    Newell, KA
    Woodle, ES
    Millis, JM
    Piper, JB
    Seaman, DS
    Huss, E
    Thistlethwaite, JR
    [J]. TRANSPLANTATION PROCEEDINGS, 1995, 27 (06) : 3118 - 3118